I'm pretty sure they don't. Since I don't recall any quarterly or annual reports showing an R&D budget, I have a guess as to how the "new formula" was created and tested, though.
Agreed. Just because something's a dud, you don't tell people if you're going to try to sell them your shares in that dud. That's just dumb. Probably better to hype up the product regardless of the facts.
If we take FSNR at their word, we know a few things: 1) Petrozene is a great solvent that can greatly benefit several aspects of oil production (and storage). 2) The product has been tested successfully several times by potential customers. 3) None of those potential customers have ordered any based on their testing.
The best-case conclusion (assuming, of course, that the above 3 points are true) is that Petrozene is currently over-priced based on the benefits it provides (at least compared to available alternatives).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.